12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Oseni alogliptin/pioglitazone regulatory update

FDA approved Oseni alogliptin/pioglitazone from Takeda as an adjunct to diet and exercise to improve blood sugar control in adult Type II diabetics. The pharma plans to launch the product this summer. The drug's label includes a...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >